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Abstract:  Problem  statement:  Organ  transplantation  is  a  life-saving  and  increasingly  common 
procedure, as it often serves as the only treatment available for end-stage organ disease. Although the 
constant development of new and more effective immunosuppressive drugs has revolutionized the 
prevention and treatment of acute graft rejection, these drugs have significant toxicity, greatly increase 
patient  susceptibility  to  neoplasms  and  infection  and  exert  little  impact  on  chronic  rejection. 
Approach: The literature was reviewed to illuminate the mechanisms by which the anti-donor immune 
response is initiated and how cellular therapies impact this response. Results: Data show that Donor 
Specific Transfusion, Apoptotic Cell therapies and Dendritic Cell therapies all function as a source of 
alloantigen to suppress the anti-donor T cell response. Conclusion: Cellular therapies hold promise in the 
prevention of solid organ allograft rejection, but require optimization and study in large animal models 
before clinical implementation. 
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INTRODUCTION 
 
  Organ  transplantation  is  becoming  an  increasingly 
important  and  common  surgical  procedure,  as 
transplantation surgery often serves as the only life-saving 
treatment available for end-stage organ disease. Although 
the  constant  development  of  new  and  more  effective 
immunosuppressive drugs along with better knowledge of 
their  therapeutic  application  have  revolutionized  the 
prevention  and  treatment  of  acute  graft  rejection,  these 
drugs have significant toxicity and greatly increase patient 
susceptibility  to  malignant  neoplasias  and  infections. 
Further, the implementation of immunosuppressive agents 
has  exerted  little  impact  on  the  incidence  of  chronic 
rejection and therefore overall long-term graft survival has 
only improved modestly. Novel cell-based therapies that 
are  able  to  down-regulate  the immune response against 
donor  Antigen  (Ag),  without  inducing  generalized 
immune suppression and its harmful side-effects, represent 
a promising avenue of research in transplantation. Cell-
based therapies include Donor Specific Transfusion (DST) 
(the  transfusion  of  donor  peripheral  blood  mononuclear 
cells), donor-derived apoptotic cell therapy and negative 
immunization with donor- (or recipient-) derived Dendritic 
Cells (DC). DC-based therapies in particular have received 
significant attention over the past decade as possibly ideal 
therapeutics in transplantation. Recent data though have 
shown  that  DC-based  therapy,  like  DST  and  apoptotic 
cell-based therapies all function via a similar mechanism, 
that  is  as  a  source  of  alloantigen  for  presentation  by 
recipient Ag-Presenting Cells (APC) to T cells. 
 
Basics of solid organ transplantation: Allografts are 
grafted  organs/tissues/cells  transplanted  between 
genetically disparate, MHC-mismatched individuals of 
the  same  species.  The  targeted  Ag  are  called 
alloantigens  (alloAg),  are  derived  from  Major 
Histocompatibility  Complex  (MHC)  or  minor 
histocompatibility  Ag  and  are  recognized  by  the 
adaptive  immune  response  as  non-self,  or  tissue 
incompatible  (Afzali  et  al.,  2007).  Allo-recognition 
describes  recognition  of  the  allogeneic  Ag  by  the 
recipient immune system and allo-response refers to the 
effector  mechanisms  recruited  in  the  reaction  to  the 
transplanted cell/tissue/organ (Afzali et al., 2007).  
  Allografts are threatened by three types of rejection 
that  are  defined  by  both  tempo  of  onset  and 
histopathology.  Hyperacute  rejection  occurs  within 
minutes to h (usually within 48 h) after transplantation 
surgery  and  is  mediated  by  deposition  of  pre-formed 
circulating  antibodies  against  Ag  on  graft  vascular 
endothelial  cells  and  the  consequent  activation  of Am. J. Immunol., 8 (2): 52-64, 2012 
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complement  and  coagulation  cascades,  resulting  in 
intravascular  thrombosis,  ischemia  and  necrosis.  This 
results  from  pre-sensitization  of  the  recipient,  by 
previous  blood  transfusion,  organ  transplant,  or 
pregnancy and in 1% of the general population for no 
known  reason.  Hyperacute  rejection  is  largely 
preventable due to screening for antibodies against non-
self  HLA  phenotypes  and  cross-matching,  with 
subsequent  pre-transplantation  plasmaphoresis  if 
necessary (Gallon et al., 2002; Magee, 2006).  
  Acute  rejection  begins  within  weeks  or  months  (5 
days to 3 months is typical), or in rare cases even years, 
following  transplantation  and  constitutes  the  main 
immediate threat to allograft survival. It is mediated by 
both innate and adaptive immune responses, however the 
advent  of  immunosuppressive  drugs  renders  acute 
rejection  largely  preventable.  Histopathology  reveals 
diffuse interstitial infiltrate of CD4
+ and CD8
+ T cells with 
activated or memory phenotype (Ibrahim et al., 1995). 
  Chronic  rejection  develops  in  months  or  typically 
years post-transplantation and is the most common cause 
of graft loss one year after transplantation (Pascual et al., 
2002; Sayegh and Carpenter, 2004). It results from both 
immune  and  non-immune  factors.  Typical  features  of 
chronic  rejection  include  steady  decline  of  organ 
function,  interstitial  fibrosis,  chronic  inflammatory 
infiltrate (i.e., lymphocytes, plasma cells), atrophy and 
gradual loss of parenchymal cells and chronic vascular 
arteriopathy,  the  latter  a  condition  manifested  by 
endothelitis, intimal proliferation, elastic fiber disruption, 
fibrosis and leukocyte infiltration of medium- and small-
size  arteries  of  the  graft  (Pascual  et  al.,  2002). 
Unfortunately, current immunosuppression protocols are 
ineffective at preventing or treating chronic rejection. 
  The  development  and  introduction  of 
immunosuppressive  drugs  in  the  1980s  has  greatly 
reduced the risk of acute rejection. Steroids, calcineurin 
inhibitors  such  as  tacrolimus  and  cyclosporine  that 
block  TCR-dependent  T  cell  activation,  the  MTOR 
inhibitor  sirolimus,  mycophenylate  mofetil  which 
inhibits purine biosynthesis and lymphocyte-depleting 
antibodies  are  currently  employed  in  the  clinic  to 
prevent or mitigate acute rejection with great success. 
However,  these  agents  non-specifically  suppress  the 
immune  system,  thus  greatly  increasing  patient 
susceptibility  to  opportunistic  infections  and  various 
cancers.  Further,  currently  employed 
immunosuppressive  regimens  offer  little  protection 
against chronic rejection and have significant toxicity. 
Clearly,  generation  of  therapeutics  capable  of  donor 
Ag-specific  suppression  is  ideal,  if  not  necessary  to 
reduce dependence on chronic pharmacologic agents. 
 
Immune  mechanisms  of  allograft  rejection:  The 
diversity and robustness of the alloresponse constitute 
major challenges to preventing graft rejection. Both the 
innate and adaptive immune responses are contributory. 
Mechanisms of graft damage include contact-dependent 
T  cell  cytotoxicity,  granulocyte  activation  by  Th1  or 
Th2 cytokines, NK cell-mediated cytotoxicity, delayed-
type  hypersensitivity  like  reaction  and  allo-Ab  and 
complement activation (Moine et al., 2002).  
 
Ischemia-reperfusion  injury:  Ischemia-reperfusion 
injury refers to tissue damage resulting from the return of 
blood supply to tissue after a period of ischemia. This 
injury is Ag-independent and is responsible for initiating 
the events associated with rejection. Land et al. (1994) 
developed the “injury hypothesis” by showing that intra-
operative  treatment  of  cadaver-derived  renal  allografts 
with a  free-radical scavenger reduced the incidence of 
acute  rejection  and  improved  long-term  graft  outcome 
(Land  et  al.,  1994).  Tissue  injury  up-regulates  pro-
inflammatory  mediators,  inducing  a  robust  innate 
immune  response  that  in  turn  further  promotes 
inflammation (LaRosa et al., 2007). The innate immune 
response  occurs  prior  to  and  independently  of  the 
adaptive immune response (Christopher et al., 2002; He 
et al., 2002; 2003), as RAG-deficient cardiac transplant 
recipients  experience  comparable  cellular  infiltration, 
chemokine  receptor  expression  and  pro-inflammatory 
cytokine expression with wild-type recipients 1 day post-
transplantation (He et al., 2002). 
  Innate  immune  cells  express  non-rearranged 
pattern  recognition  receptors  that  recognize  not  only 
conserved  pathogen-derived  molecules,  as  originally 
appreciated  (Medzhitov  and  Janeway,  2002)  but  also 
self-derived  molecules  released  from  damaged  or 
stressed  tissue  (Mollen  et  al.,  2006).  Optimal 
inflammatory responses to liver damage by ischemia-
reperfusion  injury  requires  signaling  through  toll-like 
receptor 4 (TLR4) expressed on hematopoietic-derived 
phagocytes and activated by products of necrotic cells 
or extracellular matrix disruption (Shen et al., 2005a; 
2005b;  Tsung  et  al.,  2005a;  Zhai  et  al.,  2004). 
Interestingly,  in  humans,  studies  of  lung  transplant 
patients  and  kidney  transplant  recipients  that  are 
heterozygous  for  either  of  two  TLR4  functional 
polymorphisms  associated  with  LPS 
hyporesponsiveness both  showed a reduced incidence 
of  acute  allograft  rejection  (Ducloux  et  al.,  2005; 
Palmer et al., 2003). This is likely due to abundance of 
various redundant danger signals. Levels of the danger 
signal  High-Mobility  Group  Box  1  (HMGB1)  are 
increased following liver ischemia-reperfusion injury as 
early as 1 h following transplantation and neutralization 
of  HMGB1  decreases  markers  of  liver  inflammation 
(Tsung  et  al.,  2005b).  Likewise,  inhibiting  signals  of 
receptor  for  Advanced  Glycation  End  products 
(RAGE), the receptor for HMGB1, prolongs survival of 
fully allogeneic cardiac allografts (Moser et al., 2007). Am. J. Immunol., 8 (2): 52-64, 2012 
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  Notably,  danger  signals  seem  to  persist  within 
allografts long after transplantation, as T cell-deficient 
mice  transplanted  with  mismatched  skin  or  cardiac 
allografts that are allowed to heal for 50 days, rapidly 
reject their grafts upon T cell reconstitution (Anderson 
et  al.,  2001;  Bingaman  et  al.,  2000).  If  homeostatic 
proliferation is taken into account using a model devoid 
of secondary lymphoid organs but containing a normal 
T  cell  compartment,  allografts  display  histological 
evidence  of  chronic  rejection,  but  are  not  acutely 
rejected (Chalasani et al., 2004).  
 
Innate  immune  response:  Polymorphonuclear  cells 
(PMN),  or  neutrophils,  rapidly  infiltrate  allografts 
following  surgery  and  ischemia/reperfusion  injury. 
Neutrophils  have  numerous  cytotoxic  and  pro-
inflammatory  mechanisms,  including  release  of  pro-
inflammatory  cytokines  and  chemoattractants  and 
production of reactive oxygen and nitrogen species. In a 
rat  liver  model  of  ischemia-reperfusion  injury, 
depletion  of  neutrophils  abrogates  tissue  damage 
(Jaeschke  et  al.,  1990)  and  neutralization  of 
KC/CXCL1,  a  potent  neutrophil  chemoattractant, 
decreases PMN infiltration and prolongs graft survival 
(Morita et al., 2001). 
  NK cells are also important contributors to allograft 
rejection.  Based  on  the  ‘missing  self’  hypothesis,  NK 
cells  recognize  cells  lacking  expression  of  self-MHC 
class I molecules. NK cells are not sufficient to reject 
solid organ allografts, as Rag-/- or SCID mice, that lack 
T  and  B  cells,  fail  to  reject  skin  or  heart  allografts 
(Bingaman et al., 2000; Kitchens et al., 2006). NK cells 
do  however  contribute  to  tissue  damage  and  amplify 
graft  inflammation  through  release  of  the  pro-
inflammatory cytokines IFN-g and TNF-a and through 
contact-mediated  cytotoxicity  (Obara  et  al.,  2005). 
Further,  NK  cell  depletion  in  CD28-/-  mice,  whose  T 
cells are unable to receive co-stimulation, prolongs fully 
MHC-mismatched  cardiac  allograft  survival  (Maier  et 
al.,  2001),  suggesting  that  NK  cells  influence  the 
adaptive immune response (McNerney et al., 2006).  
  Macrophages  (MF)  are  also  believed  to  be 
important for rejection, although their importance may 
be  organ  or  model  dependent.  MF  contribute  to  an 
inflammatory  response  in  multiple  ways.  They 
phagocytose necrotic debris, secrete pro-inflammatory 
cytokines,  produce  reactive  nitrogen  and  oxygen 
species and present Ag to effector T cells (Wyburn et 
al., 2005). In rat renal allografts, MF begin infiltrating 
allografts within 24 h following surgery and proliferate 
in  situ  (Grau  et  al.,  1998)  and  in  human  acute  renal 
rejection,  MF  accumulate  in  significant  numbers 
(Hancock et al., 1983). Also in a rat renal transplant 
model,  liposomal  clodronate  administration  1  d  post-
transplantation,  which  depletes  the  majority  of  MF, 
reduces allograft damage (Jose et al., 2003), although 
liposomal  clodronate  also  depletes  other  subsets  of 
monocytes and DC thus complicating interpretation of 
the data. The production of iNOS in particular seems 
important  for  allograft  rejection,  as  its  neutralization 
prolongs cardiac allograft survival in mice (Roza et al., 
2000; Worrall et al., 1995).  
 
Adaptive immune response: There are two mechanisms 
by  which donor-reactive T cells recognize  alloAg: the 
direct and the indirect pathways of allorecognition (Fig. 
1)  (Game  and  Lechler,  2002).  By  the  direct  pathway, 
recipient T cells recognize intact donor MHC molecules 
expressed  on  the  surface  of  donor  APC  transplanted 
along  with  the  allograft  (i.e.  donor  DC,  macrophages, 
endothelial  cells)  (Lombardi  et  al.,  1989).  Ischemia-
reperfusion injury and surgical trauma activate donor DC 
inducing  their  migration  as  “passenger  leukocytes”  to 
recipient secondary lymphoid organs, where they prime 
donor-reactive  T  cells  (Anderson  et  al.,  2001).  The 
precursor  frequency  of  direct  pathway  T  cells  is 
extremely high, roughly 1-10% (Baker et al., 2001) of 
the T cell pool. This direct  T cell alloreactivity likely 
results  from  cross-reactivity  between  intact  allogeneic 
MHC  molecules  and  self-MHC-foreign  peptide 
complexes (Lombardi et al., 1989).  
  By the indirect pathway, recipient T cells recognize 
self-MHC  molecules  presenting  donor-derived 
allopeptides on recipient APC (Benichou et al., 1992; 
Liu et al., 1996). The precursor frequency of indirect 
pathway T cells is extremely low (1:100,000-200,000) 
and similar to that for any other conventional/nominal 
Ag.  It  is  unknown  whether  recipient  APC  mobilized 
into the graft acquire alloAg, then traffic to secondary 
lymphoid organs to prime indirect pathway T cells, or 
whether  alloAg  derived  from  the  graft,  either  in  the 
form  of  passenger  leukocytes  or  soluble  MHC 
molecules, enters secondary lymphoid organs where it 
is taken up by lymphoid-resident DC for presentation. 
Either  way,  recipient  APC  internalize  donor  Ag  and 
process it into peptide for presentation by self-MHC to 
indirect pathway T cells. 
  Recently,  a  third  “semi-direct”  pathway  of 
allorecognition  has  been  identified  in  mouse  models. 
By  the  semi-direct  pathway,  intact  donor  MHC 
molecules  are  acquired  by  recipient  APC  and  are 
presented intact to direct pathway T cells (Herrera et 
al., 2004).  
  The  semi-direct  pathway  is  one  proposed  model 
challenging the existing paradigm that direct pathway T 
cells are primed independently of recipient APC and the 
indirect pathway (Fig. 2a, d). Alternatively, the 4-cell 
hypothesis  suggests  that  indirect  pathway  CD4
+  T 
helper  cells  stimulated  by  recipient  APC  provide 
unlinked bystander help to direct pathway CD8
+ T cells 
stimulated by donor APC (Fig. 2b, c). Indirect CD4
+ T 
cells could also provide CD40-mediated stimulation of Am. J. Immunol., 8 (2): 52-64, 2012 
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recipient  APC  that  in  turn  might  stimulate  the  direct 
pathway  response  through  an  unknown  mechanism 
(Fig. 2b), or via interaction between a B cell receptor, if 
the  recipient  APC  were  a  B  cell,  with  donor 
MHC:alloAg on the surface of donor APC (Fig. 2c).  
  T cells are both necessary and sufficient for allograft 
rejection  of  almost  all  tissues.  Acute  graft  rejection  is 
considered  T  cell  dependent,  as  several  studies 
demonstrate that mice lacking T cells accept fully MHC-
mismatched  allografts  and  that  T  cell  reconstitution 
results in rejection. Due to the high precursor frequency 
of  direct  pathway  T  cells  (approximately  1000  fold 
greater than indirect pathway T cells), it is assumed that 
the direct pathway is the more significant contributor of 
acute  rejection  (Larsen  et  al.,  1990;  Lechler  and 
Batchelor, 1982; Talmage et al., 1976). However, as the 
supply of donor APC within the graft wanes over time, 
the contribution of the direct pathway decreases. Human 
studies  confirm  that  the  direct  pathway  response  is 
strongest  in  the  period  immediately  following 
transplantation. Comparatively, alloAg is shed from the 
graft  continuously  and  due  to  epitope  spreading 
(Ciubotariu et al., 1998), the significance of the indirect 
pathway increases (Valujskikh et al., 1998). As such, it is 
considered the main mediator of chronic rejection, which 
is  confirmed  in  human  studies  of  chronically  rejected 
heart, kidney and lung (Ciubotariu et al., 1998; Frasca et 
al., 1998; Hornick et al., 2000; Lee et al., 2001; Liu et 
al., 1996; Reznik et al., 2001; Valujskikh et al., 1998; 
Vella et al., 1997).  
  Notably, there is evidence supporting the ability of 
the  indirect  pathway  to  mediate  acute  rejection.  In 
human recipients of heart, kidney and liver allografts, in 
vitro  detection  of  the  indirect  response  shows  strong 
correlation with episodes of rejection (Dalchau et al., 
1992; Vella et al., 1997) and immunization of animals 
with  peptide  derived  from  allogeneic  MHC  (thus 
presented through the indirect pathway) causes allograft 
rejection  (Fangmann  et  al.,  1992a;  1992b).  Finally, 
using  a  cardiac  allograft  transplant  model  in  mice, 
Auchincloss  et  al.  (1993)  showed  that  the  indirect 
pathway  is  sufficient  to  elicit  graft  rejection  in  the 
absence  of  direct  allorecognition  (Auchincloss  et  al., 
1993).  The  relative  contributions  of  the  indirect  and 
direct  pathway  were  evaluated  in  skin,  cornea  and 
retina  and  results  reveal  that  the  importance  of  each 
pathway appears to be organ dependent (Illigens et al., 
2002). As expected, skin allografts have a pronounced 
direct pathway response, likely attributable to their high 
passenger APC load. Comparatively, cornea had a more 
potent indirect pathway response, again not surprising 
given its low level of MHC molecule expression. Such 
studies are yet to be performed in heart transplantation, 
although  given  the  low  number  of  passenger 
leukocytes, one might expect increased importance of 
the indirect response. 
  T cells contribute to allograft rejection by various 
mechanisms.  Contact  mediated  cytotoxicity  and 
release of pro-inflammatory cytokines are both potent 
mechanisms  of  allograft  damage.  Typically,  the 
allograft  response  is  Th1,  IFN-g  mediated,  however 
both  Th1  and  Th2  effector  responses  can  cause 
allograft  rejection  (Moine  et  al.,  2002).  Further,  T 
cells stimulate other immune cells to cause damage. B 
cell  function  and  the  alloAb  response  depends  on 
indirect  pathway  CD4
+  T  cell  help  because  B  cells 
recognizing  Ag  via  B  cell  receptors  internalize, 
process and present antigenic peptides loaded in self-
MHC to T cells, that in turn, provide the necessary 
help  for  B  cell  effector  function  and  Ab  class 
switching  (Steele  et  al.,  1996;  Terasaki,  2003). 
Indirect pathway T cells could also stimulate recipient 
MF  or  DC  within  the  graft  to  release  pro-
inflammatory molecules in a DTH-like response. This 
previously has been associated with chronic rejection, 
however  it  is  possible  that  the  cytotoxic  molecules 
released  by  MF/DC  could  contribute  to  acute 
rejection,  particularly  since  one  stimulated  MF/DC 
could  damage  numerous  surrounding  donor  cells 
simultaneously,  while  one  CD8
+  cytotoxic  T  cell 
targets only one donor cell at a time.  
 
Cellular  therapies  in  solid  organ  transplantation: 
The  concept  of  utilizing  cellular  therapies  to  induce 
allograft tolerance has its roots in the earliest studies of 
transplantation.  Billingham  et  al.  (1953)  showed  that 
infusion of donor allogeneic cells into newborn  mice 
resulted in acceptance of skin allografts in the absence 
of immunosuppression (Billingham et al., 1953). More 
recently, Sayegh et al. (1993) demonstrated that intra-
thymic  injection  of  donor  allopeptides  prolongs 
subsequent  allografts  of  the  same  MHC,  further 
indicating that exposure of recipients to donor Ag prior 
to  transplantation  has  a  tolerizing  effect.  Currently, 
there are three types of cellular therapies proposed for 
use  in  transplantation.  Donor-Specific  Transfusion 
(DST)  refers  to  the  transfer  of  donor  splenocytes  in 
mice, or peripheral blood mononuclear cells in humans, 
directly from donor to recipient with little manipulation. 
DST has been employed in the clinic for decades and in 
some  cases  successfully  decreased  the  anti-donor 
immune  response  and  prolonged  allograft  survival. 
However,  prevention  of  acute  rejection  was  not 
universally achieved and DST was associated with risk 
of  recipient  sensitization,  thus  the  advent  of 
pharmacologic  immunosuppressive  agents  replaced 
DST  as  the  main  prophylactic  for  transplant 
recipients.  Ironically,  the  negative  side  effects  of 
pharmacologic immunosuppression coupled with the 
new goal of achieving operational tolerance, defined 
as  long-term  freedom  from  all  immunosuppression 
with normal graft function, has resulted in a renewed 
interest in cellular therapies. Am. J. Immunol., 8 (2): 52-64, 2012 
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Fig. 1:  Pathways of allorecognition. In the direct pathway, donor DC directly interact with anti-donor T cells. In 
this case, T cells recognize  alloMHC: peptide complexes on the surface of donor DC. In  the  indirect 
pathway, recipient DC re-process donor alloAg derived from donor APC into allopeptide for presentation 
by self-MHC to anti-donor T cells.  
 
 
 
Fig. 2:  Models of direct pathway CD8
+ T cell priming. (a) Direct pathway T cells are primed by donor APC 
independently of recipient APC or indirect T cells. (b) Indirect pathway CD4
+ helper T cells stimulated by 
recipient APC provide unlinked bystander help to direct pathway CD8
+ T cells stimulated by donor APC. 
(c,  d)  Indirect  CD4
+  T  cells  provide  CD40-mediated  stimulation  of  recipient  APC  that  in  turn  might 
stimulate the direct pathway response via (c) interaction between a B cell receptor, if the recipient APC 
were a B cell, or (d) a recipient DC with donor MHC:alloAg on its surface. Am. J. Immunol., 8 (2): 52-64, 2012 
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Advancements  in  understanding  peripheral  tolerance 
mechanisms has led to development of newer cellular 
therapies  including  donor  apoptotic  cell  therapy  and 
tolerogenic DC therapies. 
 
DST  in  transplantation  of  solid  organ  allografts: 
Quezada et al. (2003) showed that DST significantly 
prolongs  skin  allograft  survival  through  peripheral 
deletion of indirect pathway CD4
+ T cells and increased 
numbers  of  regulatory  T  cells  (Treg).  Brouard  and 
Soulillou and colleagues demonstrated that infusion of 
splenocytes  without  additional  immunosuppression 
leads to long-term survival of cardiac allografts through 
expansion  of  Treg  and  that  transfer  of  long-term 
survivor  splenic  T  cells  to  new  allograft  recipients 
transfers long-term allograft survival in an Ag-specific 
manner (Lair et al., 2007). Importantly, in the Quezada 
study,  the  injected  living  donor  splenocytes  did  not 
directly  interact  with  CD4
+  T  cells  (Quezada  et  al., 
2003).  This  finding  suggests  that  living  splenocytes 
upon  i.v.  injection  in  some  way  transfer  alloAg  to 
recipient APC for indirect presentation rather directly 
interacting with direct pathway T cells.  
 
Apoptotic  cell  therapy  in  transplantation  of  solid 
organ allografts: Our group has investigated apoptotic 
cell therapy in allograft survival and demonstrated in 
mice  that  i.v.  administration  of  donor-derived  UV-B-
irradiated  apoptotic  splenocytes  7  d  prior  to 
transplantation significantly prolongs survival of heart 
allografts in the absence of immunosuppression (Wang 
et al., 2006). Moreover, combination of donor apoptotic 
splenocytes  with  suboptimal  blockade  of  the  CD40-
CD154 pathway with a single dose of anti-CD154 Ab 
results in long-term survival of cardiac transplants for 
more than 100 d (Wang et al., 2006). The therapeutic 
effect of donor apoptotic cells was donor-specific and 
required interaction of the apoptotic cells with recipient 
DC in secondary lymphoid organs. It also depended on 
the physical properties of the donor leukocytes, since 
administration  of  donor  necrotic  cells  did  not  affect 
graft  survival  (Wang  et  al.,  2006).  We  further 
demonstrated  that  i.v.  administered  donor-apoptotic 
cells are rapidly phagocytosed by recipient splenic DC, 
which  present  apoptotic  cell-derived  allopeptides  in 
self-MHC  to  indirect  pathway  T  cells  (Wang  et  al., 
2006).  Interestingly,  splenic  transgenic  CD4
+  T  cells 
specific  for  indirect  pathway  Ag  proliferated  in 
response to injection of BALB/c apoptotic splenocytes, 
but  did  not  upregulate  expression  of  the  T  cell 
activation markers CD25, CD44, CD69 and CD152 and 
secreted lower amounts of IL-2 and IFN-g upon ex vivo 
re-stimulation when compared to controls. Importantly, 
the defective activation of anti-donor indirect pathway 
CD4
+  T  cells  resulted  in  their  peripheral  deletion,  as 
their  numbers  decreased  significantly  in  spleen,  LN, 
blood and peripheral tissues, 14 d after administration 
of apoptotic cells.  
  Besides  inducing  peripheral  deletion  of  donor-
reactive  T  cells,  administration  of  donor  apoptotic 
splenocytes  in  combination  with  suboptimal  CD40-
CD154 blockade promotes differentiation/expansion of 
donor-specific CD4
+ Treg (Wang et al., 2006), reduces 
significantly the level of circulating alloAb in cardiac 
allograft  recipients  (Wang  et  al.,  2006)  and  in  aortic 
allograft transplantation, a model of chronic rejection, 
results in significant inhibition of the histopathological 
features  of  chronic  vascular  arteriopathy,  the  classic 
feature of chronic rejection (Wang et al., 2009). 
 
Dendritic cell-based therapies in transplantation of 
solid  organ  allografts:  DC  are  a  heterogeneous 
population  of  hematopoietic-derived  APC  that 
orchestrate the adaptive immune response to self- and 
foreign-Ag.  DC  are  defined  by  surface  expression  of 
MHC class-II molecules, expression of the integrin and 
complement receptor CD11c (in mice) and their unique 
ability  to  stimulate  naïve  T  cells  (Banchereau  et  al., 
2000). DC respond to both endogenous and exogenous 
danger signals such as pathogen-associated  molecular 
patterns  on  microorganisms,  products  secreted  by 
activated  MF  and  parenchymal  cells  and  stimulatory 
signals from activated T cells (Banchereau et al., 2000). 
Since they are the only APC capable of priming naïve T 
cells, they serve as a crucial link between innate and 
adaptive  immunity  (Banchereau  et  al.,  2000; 
Banchereau and Steinman, 1998).  
  In the periphery, DC exist in 3 different stages of 
activation/maturation:  immature,  semi-mature  or 
quiescent  and  mature  or  activated  (Fig.  3).  In  the 
steady-state,  quiescent  DC  are  highly  phagocytic  and 
express low surface levels of MHC : peptide complexes 
and  the  co-stimulatory  molecules  CD80  and  CD86 
(Banchereau  et  al.,  2000;  Banchereau  and  Steinman, 
1998; Cella et al., 1997). DC mature upon exposure to 
pro-inflammatory  stimuli.  During  maturation,  DC 
decrease phagocytic ability and increase their surface 
expression of MHC class-I and -II: peptide complexes, 
CD40, CD80 and CD86 (Cella et al., 1997). The MHC: 
peptide  complexes  presented  by  DC  bind  the  T  cell 
receptor (TCR) (signal 1), while CD80 and CD86 bind 
CD28  (signal  2)  on  the  surface  of  the  T  cell.  This 
induces secretion of IL-2, which is a potent agonist for 
T cell activation/proliferation (Lenschow et al., 1996). 
Additionally, the interaction between CD40 on the DC 
and  CD40Ligand  (CD40L  or  CD154)  on  the  T  cell 
surface  further  enhances  DC  and  T  cell  stimulation 
(Grewal and Flavell, 1998).  Am. J. Immunol., 8 (2): 52-64, 2012 
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Fig 3:  Stages of DC maturation. DC can exist as either immature (express low levels of MHC: peptide complex 
without  co-stimulatory  molecules  CD80  or  CD86),  semi-mature  or  quiescent  (express  low  levels  of 
MHC:peptide complex along with low levels of co-stimulatory molecules), or mature or activated (express 
high levels of MHC:peptide complex and high levels of co-stimulatory molecules). 
 
Mature DC secrete soluble mediators (signal 3) which 
help  direct  the  immune  response,  such  as  IL-12p70, 
which  polarizes  T  cells  toward  a  Th1  response 
(Banchereau  et  al.,  2000;  Banchereau  and  Steinman, 
1998; Cella et al., 1997). 
 
DC as inducers of T cell tolerance: Although most T 
cells  recognizing  self-peptides  with  high  affinity  are 
eliminated  centrally  in  the  thymus  through  negative 
selection (Brocker et al., 1997), a percentage of self-
reactive T cells escape thymic deletion and access the 
periphery. An efficient mechanism in the periphery is 
therefore necessary to prevent activation of self-reactive 
T cells and avoid autoimmunity.  
 
Quiescent  DC  expressing  MHC:  Peptide  complexes 
(signal  1)  with  low  levels  of  co-stimulatory  signals 
(signal  2)  provide  sub-threshold  stimulation  to  auto-
reactive T cells, resulting in defective T cell activation 
(Schwartz, 1990; Steinman et al., 2003; Steinman and 
Nussenzweig,  2002).  Incomplete  T  cell  activation 
results  in  poor  cellular  proliferation  followed  by 
deletion, anergy and likely differentiation/expansion of 
Treg  cells,  all  mechanisms  leading  to  T  cell  hypo-
responsiveness  or  tolerance  (Steinman  et  al.,  2003; 
Steinman and Nussenzweig, 2002). 
 
DC  therapies  in  transplantation  of  solid  organ 
allografts: The ability of DC to tolerize T cells in an 
Ag-specific  manner,  coupled  with  the  ability  to 
propagate large numbers of DC in vitro, has heralded 
the  use  of  tolerogenic/immunosuppressive  DC  as 
therapeutics  for  transplantation  and  autoimmunity. 
Tolerogenic DC are in an immature or quiescent state, 
in  that  they  express  low  levels  of  MHC:  peptide 
complexes  with  or  without  low  amounts  of  co-
stimulatory molecules (Fig. 3) and are impaired in their 
ability to produce the Th1-driving cytokine IL-12p70. 
A  number  of  methods,  including  culture-conditioning 
with  different  cytokines  or  growth  factors,  treatment 
with  various  pharmacologic  agents  and  genetic 
engineering  (Table  1)  (Morelli  and  Thomson,  2007) 
have been developed to increase DC tolerizing potential 
and/or render tolerogenic DC resistant to maturation, to 
combat  the  risk  of  in  vivo  maturation  of  the 
administered DC and thus patient sensitization.  
  These  pharmacologic  or  genetic  manipulations 
affect  DC  differentiation  and  function  by  various 
mechanisms  (Morelli  and  Thomson,  2007).  Some 
tolerogenic  DC  express  high  levels  of  co-inhibitory 
molecules such as PD-L1 on their surface, or have a 
lower  net  ratio  of  co-stimulatory  to  co-inhibitory 
molecule expression (i.e., CD86 : PD-L1). Secretion of 
inhibitory cytokines/mediators also is variable, as some 
tolerogenic DC release IL-10, which has been shown to 
inhibit  T  cell  expansion  (Li  et  al.,  2005).  Further, 
tolerogenic DC can induce activation-induced cell death 
through FasL expression or induce Treg through IDO 
expression (Bohana-Kashtan and Civin, 2004; Mellor et 
al., 2004). A number of different types of tolerogenic 
DC,  many  with  different  phenotypic  and  functional 
characteristics have been studied in mouse models of 
heart  transplantation  using  a  heterotopic  cardiac 
allograft  model.  These  tolerogenic  DC  therapies 
prolong allograft survival with a Mean Survival Time 
(MST) between 20 and 50 days (Emmer et al., 2006; 
Lan et al., 2006; O’Connell et al., 2002; Tang et al., 
2006; Turnquist et al., 2007). Typically, an increased 
percentage of Treg is observed along with decreased T 
cell effector responses.  Am. J. Immunol., 8 (2): 52-64, 2012 
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Table 1: Methods of generating tolerogenic DC in vitro 
Cytokines, growth factors  Pharmacologic mediators   Genetic engineering  
¯GM-CSF  Immunosuppresstive or anti-inflammatory drugs  Recombinant viral vectors or naked DNA: 
­IL-10  Cyclosporine  CD95L (FasL) 
­TGFb1  Rapamycin  CTLA4-Ig 
­VEGF  Tacrolimus  IL-10 
  Deoxyspergualin  TGFb1 
  Mycophenolate mofetil  IDO 
  Sanglifehrin A  Soluble TNFR 
  Corticosteroids  CCR7 
  A spirin  Dominant-negative IKB 
  1 a, 25-dihydroxyvitamin D3  Kinase 
  N-acety-L-cysteine  ODNs; 
  Cyclic AMP inducers   NF-Kb-specific decoy 
  Glucosamine  RAN interference: 
  Cobalt protoporphyrin  RELB 
  ILT receptor ligands  IL-10 
 
Although  these  different  tolerogenic  DC  vary 
phenotypically in vitro, the similar effect on allograft 
survival  and  anti-donor  T  cell  responses  suggests 
similar mechanism of action in vivo.  
  It has been assumed that therapeutic tolerogenic DC, 
once  administered  i.v.  to  prospective  graft  recipients, 
interact  directly  with  anti-donor  T  cells.  Given  the 
preponderance of the direct pathway  in acute allograft 
rejection, it has further been assumed that the ability to 
down-modulate the direct pathway response makes DC 
therapies superior to alternative cellular therapies (DST 
and apoptotic cell therapy) in transplantation.  
  Our  group  has  investigated  the  mechanisms  by 
which DC therapy functions in vivo to prolong cardiac 
allograft survival in a mouse model. We demonstrated 
that donor-derived DC rapidly die once transfused into 
the  prospective  graft  recipient  and  that  apoptotic  cell 
fragments derived from the injected therapeutic DC are 
taken up by the recipient’s DC and processed into donor 
alloAg for presentation via recipient MHC molecules to 
indirect pathway CD4
+ T cells (Divito et al., 2010). If the 
recipient  DC  are  quiescent,  then  this  process  induces 
defective  activation  of  indirect  pathway  CD4
+  T  cells 
with preferential survival of Treg (Divito et al., 2010). 
We have further shown that recipient DC are necessary 
for DC therapy prolongation of allograft survival using 
CD11c-DTR bone marrow chimeric mice to selectively 
deplete recipient but not donor DC (Wang et al., 2012). 
Finally, we showed that apoptotic cell therapy, DST and 
DC therapy all act via the same mechanism of action, 
that  is,  they  serve  as  a  source  of  donor  alloAg  for 
recipient DC, rather than through direct interaction with 
anti-donor T cells (Divito et al., 2010). 
 
A  brief  statement  on  T  cell-based  therapies  in 
transplantation:  In  addition  to  the  above  named 
cellular  therapies,  the  possibility  of  employing 
regulatory  and/or  anergic  T  cells  generated  and 
expanded in vitro, ex vivo, or even in vivo, to modulate 
the anti-graft response has received great attention over 
the past decade. Various methodologies of generating 
regulatory and/or anergic T cells have been studied in 
multiple  animal  models  of  organ  transplantation  with 
initial  promising  results  (reviewed  by  (McMurchy  et 
al.,  2011))  and  Tregs  generated  in  vitro  have  been 
utilized in clinical trials for graft-versus-host disease in 
stem  cell  transplantation,  demonstrating  its  clinical 
feasibility  (Brunstein  et  al.,  2011;  Ianni  et  al.,  2011; 
Trzonkowski  et  al.,  2009).  Given  the  expanse  of 
literature on T cell based-therapies in transplantation, as 
well  as  in  autoimmunity  and  graft-versus-host-disease, 
they will not be discussed further here, except to say that 
T cell-based therapies are a major area of research in the 
transplantation community and warrant further research. 
 
CONCLUSION 
 
  Despite  the  promising  results  of  cell-based 
therapies  in  animal  models,  it  is  important  to 
acknowledge caveats to current research and roadblocks 
to clinical translation. First, most research on cellular 
therapies in transplantation  has been conducted using 
young  inbred  mice  maintained  in  clean  or  nearly 
pathogen-free  conditions,  which  therefore  may 
possess low numbers of memory T cells compared to 
outbred  animals.  Comparatively,  transplant  rejection 
in humans is mediated by both naïve and memory T 
cells and as such, the ability of cellular therapies to 
tolerize not only recipient DC-naive T cell interaction, 
but also other non-professional recipient APC capable 
of activating anti-donor memory T cells, will likely be 
critical for successful therapy.  
  Second, safety is a major area of concern. What if a 
preparation  of  cellular  therapeutic  contained  traces  of 
effector cells? Or if a batch of the tolerizing agent was 
ineffective? And if administration of a cellular therapy Am. J. Immunol., 8 (2): 52-64, 2012 
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had a deleterious effect, could the adoptively transferred 
cell be eliminated from the patient? In reality, it is likely 
that cellular therapeutics would never be instituted in the 
clinic as a single therapy, but rather in combination with 
additional pharmacologic immunosuppression. This may 
help alleviate some of the risks associated with cellular 
products.  Further,  clinical  experience  with  cellular 
therapeutics is being gained from the fields of stem cell 
transplantation and cancer.  
  Solid  organ  transplantation  remains  a  clinical 
challenge  despite  its  increasing  prevalence.  Many 
questions remain in regards to the immunopathogenesis of 
allograft  rejection  and  whether  cellular  therapies  will 
ultimately have a role in preventing rejection. Regardless, 
optimization  and  application  of  cellular  therapies 
represents  an  active  area  of  research  in  transplant 
immunology and still holds promise for clinical use. 
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